Scott L. Burrows, the Chief Financial Officer of Spyre Therapeutics, Inc., has recently engaged in notable stock transactions that could impact the company’s market perception. The transactions, reported in a recent SEC filing, involved both the acquisition and disposal of shares, highlighting the ongoing management strategies within the pharmaceutical sector.
Background
Spyre Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies. According to the SEC filing, the company is classified under the SIC code for pharmaceutical preparations. The firm operates under the ticker symbol SYRE and is incorporated in Delaware, with its headquarters located in Waltham, Massachusetts.
What the Filing Says
The SEC filing, dated October 2, 2026, details multiple transactions by Burrows. Notably, he acquired 17,500 shares at a price of $14.50 each and disposed of 17,500 shares at a weighted average price of $89.89. Following these transactions, Burrows holds a total of 97,262 shares in Spyre Therapeutics.
Impact
These transactions may affect investor confidence and market dynamics surrounding Spyre Therapeutics. As the CFO, Burrows’ actions could signal his confidence in the company's future performance or reflect broader strategic decisions within the organization. Stakeholders and investors will likely monitor these developments closely.
What's Next
The filing does not say what happens next.